Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 35

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 35
---
1,488,680 shares of common stock issuable upon warrants (other than the Prefunded Warrants) issued in the Private Placement; |

| ● | 1 share of common stock issuable upon the conversion of outstanding shares of Series A Convertible Preferred Stock; |

| ● | 266 shares of common stock issuable upon the exercise of outstanding stock options issued pursuant to the Incentive Plan; |

| ● | 161,527 shares of common stock issuable upon the settlement of outstanding restricted stock units issued pursuant to the Incentive 
 Plan; and                                                                                                                          |

| ● | 17,978 shares of common stock reserved for future issuance under our Incentive Plan. |

<div align='center'>S-20

PLAN OF DISTRIBUTION</div>

We have entered into an At-The-Market Issuance
Sales Agreement with Lucid Capital Markets, LLC, as Sales Agent, under which we may issue and sell over a period of time, and from time
to time, shares of our common stock having an aggregate offering price of up to $1,750,000 through the Sales Agent acting as sales agent
or directly to a Sales Agent acting as principal. This prospectus supplement relates to our ability to issue and sell over a period of
time, and from time to time, shares of our common stock to or through the Sales Agent pursuant to the Sales Agreement. Sales of the shares
to which this prospectus supplement and the accompanying prospectus relate, if any, may be made in transactions that are deemed to be
“at-the-market” offerings as defined in Rule 415 under the Securities Act, including sales made directly on or through the
Nasdaq Capital Market (“Nasdaq”), the trading market for our common stock, or any other trading market in the Unites States
for our common stock, sales made to or through a market maker other than on an exchange, directly to the Sales Agent as principal for
its account in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market
prices, in privately negotiated transactions, in block trades, or through a combination of any such methods of sale. To the extent required
by Regulation M, the Sales Agent acting as our sales agent will not engage in any transactions that stabilize our common stock while the
offering is ongoing under this prospectus supplement.

Upon written instructions from us, the Sales Agent
will offer the shares of our common stock, subject to the terms and conditions of the